GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Anterogen Co Ltd (XKRX:065660) » Definitions » Cyclically Adjusted Price-to-FCF

Anterogen Co (XKRX:065660) Cyclically Adjusted Price-to-FCF : (As of Jun. 07, 2025)


View and export this data going back to 2016. Start your Free Trial

What is Anterogen Co Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Anterogen Co Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Anterogen Co's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Anterogen Co Cyclically Adjusted Price-to-FCF Chart

Anterogen Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Anterogen Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Anterogen Co's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Anterogen Co's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Anterogen Co's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Anterogen Co's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Anterogen Co's Cyclically Adjusted Price-to-FCF falls into.


;
;

Anterogen Co Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Anterogen Co's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Anterogen Co's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-70.371/122.5900*122.5900
=-70.371

Current CPI (Mar. 2025) = 122.5900.

Anterogen Co Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -67.901 100.051 -83.198
201509 26.856 100.111 32.886
201512 119.546 100.220 146.229
201603 87.161 100.561 106.255
201606 -356.022 100.791 -433.023
201609 -172.267 101.461 -208.141
201612 -383.944 101.561 -463.441
201703 43.582 102.851 51.946
201706 -41.731 102.611 -49.856
201709 -111.403 103.491 -131.963
201712 -15.930 102.991 -18.961
201803 -168.342 104.101 -198.241
201806 -150.768 104.130 -177.495
201809 -374.932 105.651 -435.047
201812 -101.743 104.351 -119.527
201903 -18.656 104.491 -21.887
201906 -37.393 104.881 -43.707
201909 -180.947 105.200 -210.858
201912 -270.308 105.121 -315.227
202003 -300.532 105.354 -349.699
202006 -425.282 105.112 -495.999
202009 -88.349 106.198 -101.986
202012 -459.760 105.765 -532.896
202103 -281.257 107.357 -321.164
202106 -123.601 107.579 -140.848
202109 -13.822 108.759 -15.580
202112 -212.940 109.676 -238.012
202203 -94.210 111.848 -103.258
202206 -54.662 114.072 -58.744
202209 37.773 114.715 40.366
202212 -124.498 115.179 -132.508
202303 -36.534 116.507 -38.441
202306 -138.082 117.182 -144.454
202309 -53.607 118.964 -55.241
202312 14.762 118.837 15.228
202403 -23.843 120.123 -24.333
202406 50.886 120.007 51.981
202409 -96.546 120.861 -97.927
202412 -53.991 121.135 -54.639
202503 -70.371 122.590 -70.371

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Anterogen Co  (XKRX:065660) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Anterogen Co Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Anterogen Co's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Anterogen Co Business Description

Industry
Traded in Other Exchanges
N/A
Address
Namsung Plaza, Gasan-dong, 405, 130, Digital-ro, Geumcheon-gu, Seoul, KOR, 08589
Anterogen Co Ltd is a bio-venture company engaged in the research and development of cell therapy products and orphan drugs using adult stem cells. Its products include Cupistem injection, Queen cell, Remodulin injection, and TheraStem-Derma. The company also offers cell banking services and analysis services that include sample analysis for clinical studies.

Anterogen Co Headlines

No Headlines